Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04741009 · ClinicalTrials.gov registry record · NA

Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing

A NA study of Sensorineural Hearing Loss and Low-Frequency Residual Hearing, sponsored by Cochlear.

Completed
Registry status
NA
Development phase
10
Enrollment target
4
Study locations

NCT04741009 is a NA study of Sensorineural Hearing Loss and Low-Frequency Residual Hearing that has completed, run by Cochlear. The registered enrollment target is 10 participants, below the 130-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04741009, a NA study of Sensorineural Hearing Loss and Low-Frequency Residual Hearing, has completed, sponsored by Cochlear.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
4
Study locations

Study Summary

The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.

Interventions

  • DEVICE CI632 Slim Modiolar Electrode

Study Locations (4)

Ohio

  • Cleveland Clinic - Cleveland
  • University Hospitals - Cleveland

Massachusetts

  • UMass Memorial Medical Center - Worcester

Missouri

  • Midwest Ear Institute - Kansas City

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2021-12-16
Est. Completion 2025-06-16
Phase NA

Sponsor

Cochlear

34 total trials

What the Registry Record Tells You About NCT04741009

The ClinicalTrials.gov registry entry for NCT04741009 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (92% lower). The listed sponsor is Cochlear, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sensorineural Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which CI632 Slim Modiolar Electrode is the first listed.

NCT04741009 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Massachusetts, Missouri.

Frequently Asked Questions

What is clinical trial NCT04741009 about?

NCT04741009 is a clinical study titled "Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing". The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.

What is the current status of trial NCT04741009?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2021-12-16. Estimated completion is 2025-06-16.

What conditions does trial NCT04741009 study?

This clinical trial studies the following conditions: Sensorineural Hearing Loss, Low-Frequency Residual Hearing.

What interventions are being tested in trial NCT04741009?

The interventions under investigation include: CI632 Slim Modiolar Electrode (DEVICE).

Who is sponsoring clinical trial NCT04741009?

This trial is sponsored by Cochlear, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04741009 being conducted?

This trial has 4 study locations across Massachusetts, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sensorineural Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.